


Stabilis



Esomeprazole sodium



Noms commerciaux

Adptor	Mexique
Axagon	Italie
Axiago	Suède
Cativa	Suède
Cronopep	Colombie, Pérou
Eliprot	Equateur
Emune	Equateur
Epral	Chili
Esio	Equateur
Esmonat	Inde, Turquie
Esoblok	Turquie
Esofax	Equateur
Esolium	Pérou
Esomep	Suisse
Esomeprazol	Chili, Colombie, Equateur, Espagne, Roumanie
Esomeprazole	Etats Unis d'Amérique
Esopral	Italie, Suède
Esopran	Pérou
Esoton Plus	Pérou
Esoz	Colombie, Inde
Ezole	Pérou
Gletop	Vénézuela
Inexium	France
Milenium	Equateur
Nexiam	Belgique, Luxembourg
Nexium	Allemagne, Arabie Saoudite, Argentine, Chili, Colombie, Egypte, Emirats Arabes Unis, Equateur, Espagne, Etats Unis d'Amérique, Grande Bretagne, Grèce, Irlande, Islande, Italie, Malaisie, Mexique, Norvège, Portugal, Roumanie, Suède, Suisse, Turquie,
Redica	Vénézuela
Refexxin	Suède



Stabilité des solutions

		4 & 8 mg/ml	< 30°C		12			2284
PVC		0,4 mg/ml	23°C		48			2270
PVC		0,4 mg/ml	4°C		5			2270
PVC		0,8 mg/ml	23°C		48			2270
PVC		0,8 mg/ml	4°C		5			2270
PVC	RL	0,4 mg/ml	23°C		48			2270
PVC	RL	0,4 mg/ml	4°C		5			2270
PVC	RL	0,8 mg/ml	23°C		48			2270
PVC	RL	0,8 mg/ml	4°C		5			2270
		0.4 & 0.8 mg/ml	< 30°C		12			2284
		0.4 & 0.8 mg/ml	< 30°C		6			2284
	RL	0.4 & 0.8 mg/ml	< 30°C		12			2284



Stabilité en mélange

PP		0.32 mg/ml	22-25°C		Methadone hydrochloride : 0.2 mg/ml	24		1506



Facteur influençant la stabilité

			2284
--	--	--	------



Compatibilités

		Esomeprazole sodium : 0.8 mg/ml		3948
		Esomeprazole sodium : 0.4 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Esomeprazole sodium Ceftobiprole medocaril sodium		4650
		Esomeprazole sodium : 0,8 mg/ml		3948

		Esomeprazole sodium : 0.8 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Esomeprazole sodium : 0,4 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Esomeprazole sodium : 0,4 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Esomeprazole sodium : 0.4 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Esomeprazole sodium : 0.8 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Esomeprazole sodium : 0,4 mg/ml Cisatracurium besylate : 1 mg/ml		3429
		Esomeprazole sodium : 0.32 mg/ml Clonidine hydrochloride : 0.0075 mg/ml		1506
		Esomeprazole sodium : 0.32 mg/ml Dobutamine hydrochloride : 8 mg/ml		1506
		Esomeprazole sodium : 0.32 mg/ml Dopamine hydrochloride : 8 mg/ml		1506
		Esomeprazole sodium : 0,4 mg/ml Doripenem : 5 mg/ml		2262
		Esomeprazole sodium : 0.32 mg/ml Epinephrine hydrochloride : 40 µg/ml		1506
		Esomeprazole sodium : 0,8 mg/ml Esmolol hydrochloride : 10 mg/ml		3879
		Esomeprazole sodium : 0.32 mg/ml Fentanyl citrate : 30 µg/ml		1506
		Esomeprazole sodium : 0.32 mg/ml Flumazenil : 0.04 mg/ml		1506
		Esomeprazole sodium : 0.8 mg/ml Fosfomycin : 30 mg/ml		4055
		Esomeprazole sodium : 0.8 mg/ml Fosfomycin : 30 mg/ml		4055
		Esomeprazole sodium : 0.32 mg/ml Furosemide : 2 mg/ml		1506
		Esomeprazole sodium : 0,8 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		4465
		Esomeprazole sodium : 0,8 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Esomeprazole sodium : 0.32 mg/ml Insulin : 1 UI/ml		1506
		Esomeprazole sodium : 1 mg/ml Insulin aspart : 1 UI/ml		1508
		Esomeprazole sodium : 1 mg/ml Insulin aspart : 1 UI/ml		1508
		Esomeprazole sodium : 0.8 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Esomeprazole sodium : 0,8 mg/ml Labetalol hydrochloride : 5 mg/ml		3879
		Esomeprazole sodium : 0.32 mg/ml Methadone hydrochloride : 0.2 mg/ml		1506
		Esomeprazole sodium : 0.8 mg/ml Metoprolol tartrate : 0.4 mg/ml		3879

		Esomeprazole sodium : 0.32 mg/ml Midazolam hydrochloride : 4 mg/ml		1506
		Esomeprazole sodium : 0.32 mg/ml Morphine hydrochloride : 1 mg/ml		1506
		Esomeprazole sodium : 0.04 mg/ml Nefopam : 0.08 mg/ml		2311
		Esomeprazole sodium : 0,8 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Esomeprazole sodium : 40 mg/ml Sugammadex : 100 mg/ml		3372
		Esomeprazole sodium : 0,8 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Esomeprazole sodium : 0.8 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Esomeprazole sodium : 0.4 mg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Esomeprazole sodium : 0,4 mg/ml Telavancin hydrochloride : 7,5 mg/ml		3254
		Esomeprazole sodium Tigecycline		3332



Voie d'administration



Bibliographie






	Type	Source
1506	Revue	Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. EJHP 2015 ;22:107-112.
1508	Revue	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2270	Revue	Kupiec TC, Aloumanis V, Ben M, Trissel LA, Chan P, Patterson J. Physical and chemical stability of esomeprazole sodium solutions. Ann Pharmacotherapy 2008 ; 42, 9: 1247-1251.
2284	Laboratoire	Esomeprazole sodium (Nexium IV®) – Summary of Product Characteristics Astra Zenaca 2007

2311	Revue	Kambia N.K, Luyckx M, Dine T, Dupin-Spriet T, Gressier B, Brunet C. Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion. J Clin Pharm Ther 2009 ; 34: 25-31.
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratoire	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3372	Revue	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anesthesiol 2013 ; 63, 1: 163-166.
3429	Revue	Foushee J.A, Fox L.M, Gormley L.R, Lineberger M.S. Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration Am J Health-Syst Pharm 2015 ; 72:483-486
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3879	Revue	Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3948	Revue	Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416?424.
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4465	Revue	Foushee A, Meredith P, Fox Laura, Wilder A. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4650	Laboratoire	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021

4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
------	-------	--



Dictionnaire

 Inhibiteur de la pompe à proton	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 Chlorure de sodium 0,9%	 Non précisée
 Heure	 Polyvinyl chlorure
 NaCl 0,9% ou glucose 5%	 Jour
RL Ringer lactate	 Non précisé
 Glucose 5%	 Stabilité en mélange
 Solvant	 Molécule
 Polypropylène	 A l'abri de la lumière
 Facteur influençant la stabilité	 Diminution
 Provoque	 Dégradation
 Compatibilités	 Changement de couleur
 Incompatible	 Nutrition parentérale (mélange binaire)
 Compatible	 Incompatibilité non précisée
 Nutrition parentérale (mélange ternaire)	 Précipitation immédiate
 Changement de couleur à 4 heures	 Turbidité en 2 heures
 Turbidité immédiate	 Turbidité en 1 heure
 Aucun	 Changement de couleur après 1 heure
 Voie d'administration	 Intraveineuse
 Perfusion intraveineuse	 Perfusion sous-cutanée
 Bibliographie	 Dictionnaire